Microbiome–metabolome dynamics associated with impaired glucose control and responses to lifestyle changes

IF 58.7 1区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
Hao Wu, Bomin Lv, Luqian Zhi, Yikai Shao, Xinyan Liu, Matthias Mitteregger, Rima Chakaroun, Valentina Tremaroli, Stanley L. Hazen, Ru Wang, Göran Bergström, Fredrik Bäckhed
{"title":"Microbiome–metabolome dynamics associated with impaired glucose control and responses to lifestyle changes","authors":"Hao Wu, Bomin Lv, Luqian Zhi, Yikai Shao, Xinyan Liu, Matthias Mitteregger, Rima Chakaroun, Valentina Tremaroli, Stanley L. Hazen, Ru Wang, Göran Bergström, Fredrik Bäckhed","doi":"10.1038/s41591-025-03642-6","DOIUrl":null,"url":null,"abstract":"<p>Type 2 diabetes (T2D) is a complex disease shaped by genetic and environmental factors, including the gut microbiome. Recent research revealed pathophysiological heterogeneity and distinct subgroups in both T2D and prediabetes, prompting exploration of personalized risk factors. Using metabolomics in two Swedish cohorts (<i>n</i> = 1,167), we identified over 500 blood metabolites associated with impaired glucose control, with approximately one-third linked to an altered gut microbiome. Our findings identified metabolic disruptions in microbiome–metabolome dynamics as potential mediators of compromised glucose homeostasis, as illustrated by the potential interactions between <i>Hominifimenecus microfluidus</i> and <i>Blautia wexlerae</i> via hippurate. Short-term lifestyle changes, for example, diet and exercise, modulated microbiome-associated metabolites in a lifestyle-specific manner. This study suggests that the microbiome–metabolome axis is a modifiable target for T2D management, with optimal health benefits achievable through a combination of lifestyle modifications.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"32 1","pages":""},"PeriodicalIF":58.7000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-025-03642-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Type 2 diabetes (T2D) is a complex disease shaped by genetic and environmental factors, including the gut microbiome. Recent research revealed pathophysiological heterogeneity and distinct subgroups in both T2D and prediabetes, prompting exploration of personalized risk factors. Using metabolomics in two Swedish cohorts (n = 1,167), we identified over 500 blood metabolites associated with impaired glucose control, with approximately one-third linked to an altered gut microbiome. Our findings identified metabolic disruptions in microbiome–metabolome dynamics as potential mediators of compromised glucose homeostasis, as illustrated by the potential interactions between Hominifimenecus microfluidus and Blautia wexlerae via hippurate. Short-term lifestyle changes, for example, diet and exercise, modulated microbiome-associated metabolites in a lifestyle-specific manner. This study suggests that the microbiome–metabolome axis is a modifiable target for T2D management, with optimal health benefits achievable through a combination of lifestyle modifications.

Abstract Image

与葡萄糖控制受损和对改变生活方式的反应相关的微生物组-代谢组动态变化
2 型糖尿病(T2D)是一种受遗传和环境因素(包括肠道微生物组)影响的复杂疾病。最近的研究揭示了 T2D 和糖尿病前期的病理生理学异质性和不同亚群,这促使我们探索个性化的风险因素。通过对两个瑞典队列(n = 1,167)的代谢组学研究,我们发现了 500 多种与血糖控制受损相关的血液代谢物,其中约三分之一与肠道微生物组的改变有关。我们的研究结果表明,微生物组-代谢组动态中的代谢紊乱是葡萄糖稳态受损的潜在介质,Hominifimenecus microfluidus 和 Blautia wexlerae 通过海马酸之间的潜在相互作用就说明了这一点。短期生活方式的改变,如饮食和运动,以生活方式特异性的方式调节微生物组相关代谢物。这项研究表明,微生物组-代谢组轴是治疗 T2D 的一个可调节目标,通过综合改变生活方式可获得最佳健康效益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nature Medicine
Nature Medicine 医学-生化与分子生物学
CiteScore
100.90
自引率
0.70%
发文量
525
审稿时长
1 months
期刊介绍: Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信